Low molecular weight fucoidan inhibits tumor angiogenesis through downregulation of HIF-1/VEGF signaling under hypoxia

Marine Drugs

Volumn 13, Issue 7, 2015, Pages 4436-4451

  Chen, Meng Chuan ^a   Hsu, Wen Lin ^b,c   Hwang, Pai An ^d   Chou, Tz Chong ^a,b,e,f  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d FISHERIES RESEARCH INSTITUTE   (Taiwan)

^e ASIA UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Angiogenesis; Bladder cancer; Hypoxia inducible factor 1 alpha; Low molecular weight fucoidan; Vascular endothelial growth factor

Indexed keywords

CD31 ANTIGEN; FUCOIDIN; HYDROGEN PEROXIDE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; LOW MOLECULAR FUCOIDIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; S6 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; HIF1A PROTEIN, HUMAN; POLYSACCHARIDE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN STABILITY; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TUMOR GROWTH; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PHYSIOLOGY; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS; VASCULARIZATION;

PHAEOPHYCEAE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOVASCULARIZATION, PATHOLOGIC; POLYSACCHARIDES; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84938269468     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md13074436     Document Type: Article

References (32)

1. Carmeliet, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
2. Potente, M.; Gerhardt, H.; Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146, 873-887.
3. Harper, J.; Moses, M. A. Molecular regulation of tumor angiogenesis: Mechanisms and therapeutic implications. Experientia 2006, 96, 223-268.
4. Hockel, M.; Vaupel, P. Biological consequences of tumor hypoxia. Semin. Oncol. 2001, 28, 36-41.
5. Le, Q. T.; Denko, N. C.; Giaccia, A. J. Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 2004, 23, 293-310.
6. Park, S. Y.; Jang, W. J.; Yi, E. Y.; Jang, J. Y.; Jung, Y.; Jeong, J. W.; Kim, Y. J. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1α stabilization under hypoxia. J. Pineal Res. 2010, 48, 178-184.
7. Semenza, G. L. HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. J. Appl. Physiol. 2000, 88, 1474-1480.
8. Tang, N.; Wang, L.; Esko, J.; Giordano, F. J.; Huang, Y.; Gerber, H. P.; Ferrara, N.; Johnson, R. S. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004, 6, 485-495.
9. Rankin, E. B.; Giaccia, A. J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008, 15, 678-685.
10. Zhong, H.; De Marzo, A. M.; Laughner, E.; Lim, M.; Hilton, D. A.; Zagzag, D.; Buechler, P.; Isaacs, W. B.; Semenza, G. L.; Simons, J. W. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 1999, 59, 5830-5835.
11. Maxwell, P. H.; Dachs, G. U.; Gleadle, J. M.; Nicholls, L. G.; Harris, A. L.; Stratford, I. J.; Hankinson, O.; Pugh, C. W.; Ratcliffe, P. J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 1997, 94, 8104-8109.
12. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721-732.
13. Kwak, J. Y. Fucoidan as a marine anticancer agent in preclinical development. Mar. Drugs 2014, 12, 851-870.
14. Atashrazm, F.; Lowenthal, R. M.; Woods, G. M.; Holloway, A. F.; Dickinson, J. L. Fucoidan and cancer: A multifunctional molecule with anti-tumor potential. Mar. Drugs 2015, 13, 2327-2346.
15. Cho, M. L.; Lee, B. Y.; You, S. G. Relationship between oversulfation and conformation of low and high molecular weight fucoidans and evaluation of their in vitro anticancer activity. Molecules 2010, 16, 291-297.
16. Liu, F.; Wang, J.; Chang, A. K.; Liu, B.; Yang, L.; Li, Q.; Wang, P.; Zou, X. Fucoidan extract derived from Undaria pinnatifida inhibits angiogenesis by human umbilical vein endothelial cells. Phytomedicine 2012, 19, 797-803.
17. Koyanagi, S.; Tanigawa, N.; Nakagawa, H.; Soeda, S.; Shimeno, H. Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem. Pharmacol. 2003, 65, 173-179.
18. El Gehani, K.; Al-Kikhia, L.; Mansuri, N.; Syrjanen, K.; Al-Fituri, O.; Elzagheid, A. Angiogenesis in urinary bladder carcinoma as defined by microvessel density (MVD) after immunohistochemical staining for factor VIII and CD31. Libyan J. Med. 2011, 6, 6016.
19. Jiang, B. H.; Liu, L. Z. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv. Cancer Res. 2009, 102, 19-65.
20. Pugh, C. W.; Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat. Med. 2003, 9, 677-684.
21. Ioachim, E.; Michael, M.; Salmas, M.; Michael, M. M.; Stavropoulos, N. E.; Malamou-Mitsi, V. Hypoxia-inducible factors HIF-1α and HIF-2α expression in bladder cancer and their associations with other angiogenesis-related proteins. Urol. Int. 2006, 77, 255-263.
22. Chan, D. A.; Giaccia, A. J. PHD2 in tumour angiogenesis. Br. J. Cancer 2010, 103, 1-5.
23. Galanis, A.; Pappa, A.; Giannakakis, A.; Lanitis, E.; Dangaj, D.; Sandaltzopoulos, R. Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett. 2008, 266, 12-20.
24. Masson, N.; Singleton, R. S.; Sekirnik, R.; Trudgian, D. C.; Ambrose, L. J.; Miranda, M. X.; Tian, Y. M.; Kessler, B. M.; Schofield, C. J.; Ratcliffe, P. J. The FIH hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity. EMBO Rep. 2012, 13, 251-257.
25. Hicklin, D. J.; Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23, 1011-1027.
26. Olsson, A. K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. VEGF receptor signaling-In control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7, 359-371.
27. Befani, C. D.; Vlachostergios, P. J.; Hatzidaki, E.; Patrikidou, A.; Bonanou, S.; Simos, G.; Papandreou, C. N.; Liakos, P. Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/AKT/TOR and MAPK pathways in prostate cancer cells. J. Mol. Med. 2012, 90, 45-54.
28. Mi, C.; Ma, J.; Shi, H.; Li, J.; Wang, F.; Lee, J. J.; Jin, X. 4', 6-Dihydroxy-4-methoxyisoaurone Inhibits the HIF-1α Pathway Through Inhibition of AKT/mTOR/p70S6K/4E-BP1 Phosphorylation. J. Pharmacol Sci. 2014, 125, 193-201.
29. Du, J.; Xu, R.; Hu, Z.; Tian, Y.; Zhu, Y.; Gu, L.; Zhou, L. PI3K and ERK-Induced Rac1 Activation Mediates Hypoxia-Induced HIF-1α Expression in MCF-7 Breast Cancer Cells. PLoS One 2011, 6, e25213.
30. Kallio, P. J.; Wilson, W. J.; O'Brien, S.; Makino, Y.; Poellinger, L. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J. Biol. Chem. 1999, 274, 6519-6525.
31. Chou, T. C. Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan. Unpublished work, 2014.
32. Hwang, P. A.; Chien, S. Y.; Chan, Y. L.; Lu, M. K.; Wu, C. H.; Kong, Z. L.; Wu, C. J. Inhibition of lipopolysaccharide (LPS)-induced inflammatory responses by Sargassum hemiphyllum sulfated polysaccharide extract in raw 264.7 macrophage cells. J. Agric. Food Chem. 2011, 59, 2062-2068.